Immune Deficiency
1
Pipeline Programs
4
Companies
3
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
1
0
0
0
0
0
Early DiscoveryClinical DevelopmentMarket
Drug Modality Breakdown
Vaccine
2100%
+ 2 programs with unclassified modality
Competitive Landscape
4 companies ranked by most advanced pipeline stage
CSL BehringIL - Bradley
1 programSalmonella typhi polysaccharide vaccinePHASE_1Vaccine1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
Qu BiologicsQBKPN SSI
CSL BehringSalmonella typhi polysaccharide vaccine
Colorado TherapeuticsMechanisms of Immune Deficiency
Clinical Trials (3)
Total enrollment: 309 patients across 3 trials
Efficacy of QBKPN Site-Specific Immunomodulator in Improving Innate Immune Function & Reducing Respiratory Tract Infection in Older Adults
Start: Apr 2023Est. completion: Feb 202672 patients
Phase 2Recruiting
Undetectable IgE as a Sentinel Biomarker for Humoral Immunodeficiency
Start: Jul 2019Est. completion: Dec 202337 patients
Phase 1Completed
Mechanisms of Immune Deficiency
Start: Oct 2020Est. completion: Dec 2023200 patients
N/AUnknown
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
1 actively recruiting trials targeting 309 patients
4 companies competing in this space
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.